Marion B. Van Der Kolk

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer.

Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.

Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 29, 2026

Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials.

Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials.

Journal: The British journal of surgery

Published: August 20, 2025

Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial.

Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial.

Journal: Annals of surgery

Published: April 28, 2025

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.

Journal: The Lancet. Oncology

Published: December 13, 2024

Barriers and facilitators of healthcare professionals in integrating shared decision-making in pancreatic cancer treatment: A network approach.

Barriers and facilitators of healthcare professionals in integrating shared decision-making in pancreatic cancer treatment: A network approach.

Journal: Cancer medicine

Published: July 02, 2024

Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.

Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.

Journal: EJNMMI research

Published: December 15, 2023

Continuous early warning score calculations can facilitate the evaluation of the condition of patients developing anastomotic leak or infection after esophageal and pancreatic resection; a cohort study.

Continuous early warning score calculations can facilitate the evaluation of the condition of patients developing anastomotic leak or infection after esophageal and pancreatic resection; a cohort study.

Journal: Current problems in surgery

Published: December 07, 2023

Are enhanced recovery protocols after pancreatoduodenectomy still efficient when applied in elderly patients? A systematic review and individual patient data meta-analysis.

Are enhanced recovery protocols after pancreatoduodenectomy still efficient when applied in elderly patients? A systematic review and individual patient data meta-analysis.

Journal: Journal of hepato-biliary-pancreatic sciences

Published: October 22, 2023

Metro Mapping: development of an innovative methodology to co-design care paths to support shared decision making in oncology.

Metro Mapping: development of an innovative methodology to co-design care paths to support shared decision making in oncology.

Journal: BMJ evidence-based medicine

Published: April 04, 2023

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.

Journal: BMC cancer

Published: January 12, 2023

Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, observational cohort study.

Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, observational cohort study.

Journal: BJS open

Published: October 22, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026